Evidence map›Paper›PMID 32467627›Full record

ArticleTranslational psychiatry2020

Ergothioneine, a metabolite of the gut bacterium Lactobacillus reuteri, protects against stress-induced sleep disturbances.

Yoshiki Matsuda, Nobuyuki Ozawa, Takiko Shinozaki, Ken-Ichi Wakabayashi, Kosuke Suzuki, Yusuke Kawano, Iwao Ohtsu, Yoshitaka Tatebayashi

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Inhibitory Effect ofBiomolecules · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yoshiki MatsudaAffective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9517-151X
Nobuyuki OzawaAffective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Takiko ShinozakiAffective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Ken-Ichi WakabayashiResearch Institute, Suntory Global Innovation Center Ltd., Kyoto, Japan.
Kosuke SuzukiResearch Institute, Suntory Global Innovation Center Ltd., Kyoto, Japan.
Yusuke KawanoGraduate School of Biological Sciences, Nara Institute of Science and Technology, Nara, Japan.ORCID http://orcid.org/0000-0002-6845-8902
Iwao OhtsuFaculty of Life and Environmental Sciences, University of Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-3553-0306
Yoshitaka TatebayashiAffective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. tatebayashi-ys@igakuken.or.jp.
Tokyo Metropolitan Institute of Medical Science · JPSuntory (Japan) · JPNara Institute of Science and Technology · JPUniversity of Tsukuba · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 15K15438MEXT | Japan Society for the Promotion of Science (JSPS) 16K04442MEXT | Japan Society for the Promotion of Science (JSPS) 25871162
6 · The paper itself

Abstract

The relationships between depression and gut microbiota, particularly those involving the immune system, have become a major focus of recent research. Here, we analyzed changes in gut microbiota and their sulfur metabolites in the feces of a depression rat model using the modified 14-day social defeat stress (SDS) paradigm. Our results showed that SDS increased fecal Lactobacillus reuteri in correlation with ergothioneine levels at around day 11, which continued for at least 1 month following SDS administration. In vitro study further revealed that L. reuteri is capable of producing ergothioneine. Although the known anti-inflammatory and anti-oxidative actions of ergothioneine suggested that the increased fecal ergothioneine levels may be related to intestinal anti-inflammatory defense mechanisms, no change was observed in the plasma ergothioneine levels during the same observation period, indicating that the defense mechanisms may not be sufficiently reflected in the body. As ergothioneine is a natural ingredient that is absorbed mainly from the upper gastrointestinal tract, we hypothesized that oral ergothioneine may exert antidepressant effects. As expected, oral administration of ergothioneine prior to and during the SDS paradigm had a preventative effect on SDS-induced depressive behaviors, such as social avoidance and depression-like sleep abnormalities, particularly those of rapid eye movement sleep. These findings indicate that ergothioneine, a metabolite of L. reuteri, may be a common substance in the microbiota-gut-brain axis that prevents stress-induced sleep disturbances, especially those associated with depression.

Indexed as

ErgothioneineGastrointestinal MicrobiomeLimosilactobacillus reuteriAnimalsBacteriaRatsSleepErgothioneine

Identifiers

PMID32467627
PMCPMC7256047
OpenAlexW3029714827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.